Literature DB >> 1984539

Imported Plasmodium falciparum malaria in American travelers to Africa. Implications for prevention strategies.

E M Lackritz1, H O Lobel, B J Howell, P Bloland, C C Campbell.   

Abstract

Data from the US National Malaria Surveillance System were analyzed to assess characteristics of travelers who acquired Plasmodium falciparum infections in Africa and evaluate the impact of chloroquine resistance on the incidence of imported malaria. Although the number of cases acquired in East Africa has stabilized, the number of imported P falciparum infections acquired in West Africa increased threefold from 1985 to 1988, and the proportion of travelers who reported failure of chloroquine prophylaxis increased from 10% to 48%. Fifty-eight percent of patients who acquired malaria in West Africa had not used chemoprophylaxis. To curb the rising incidence of P falciparum infections in American travelers, the Centers for Disease Control revised malaria prophylaxis recommendations to include the use of mefloquine in areas of chloroquine resistance. Use of malaria protection measures by travelers to West Africa must also be improved.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984539

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  4 in total

1.  Comparison of the OptiMAL test with PCR for diagnosis of malaria in immigrants.

Authors:  J Iqbal; A Sher; P R Hira; R Al-Owaish
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

2.  Comparison of three regimens for malaria prophylaxis in travellers to east, central, and southern Africa.

Authors:  J C Wetsteyn; A de Geus
Journal:  BMJ       Date:  1993-10-23

3.  Severity of imported falciparum malaria: effect of taking antimalarial prophylaxis.

Authors:  S J Lewis; R N Davidson; E J Ross; A P Hall
Journal:  BMJ       Date:  1992-09-26

4.  Chemoprophylaxis and malaria death rates.

Authors:  Gérard Krause; Irene Schöneberg; Doris Altmann; Klaus Stark
Journal:  Emerg Infect Dis       Date:  2006-03       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.